The natural history of multiple sclerosis;La historia natural de la esclerosis multiple

Revista de Neurologia

Volumn 30, Issue 10, 2000, Pages 967-972

  Kremenchutzky, M ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^c HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

Clinical forms; Multiple sclerosis; Natural history; Survival

Indexed keywords

ARTICLE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; HISTORY; MULTIPLE SCLEROSIS; SURVIVAL;

EID: 0034673897     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3010.99365     Document Type: Article

References (67)

1. Allison RS, Millar JHD. Prevalence of disseminated sclerosis in Northern Ireland. Ulster Med J 1954; 23: 1.
2. McAlpine D, Lumsden CE, Acheson ED. Multiple sclerosis: a reappraisal. Edinburgh: Livingstone; 1965.
3. Schumacher GA. Problems of experimental trials of therapy in multiple sclerosis. Report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552.
4. Rose AS, Ellison GW, Myers LW, Tourtellotte WW. Criteria for the clinical diagnosis of multiple sclerosis. Neurology 1976; 26: 20.
5. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227.
6. MacKay RP, Hirano A. Forms of benign multiple sclerosis: report of two 'clinically silent' cases discovered at autopsy. Arch Neurol 1967; 17: 588.
7. Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983; 40: 533.
8. Herndon RM, Rudick RA. Multiple sclerosis: the spectrum of severity. Arch Neurol 1986; 50: 531.
9. Sadovnik AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW, et al. A population based study of MS in twins. Update. Ann Neurol 1993; 33: 281.
10. McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961; 84: 186.
11. Méndez MF, Pogacar S. Malignant monophasic MS or Marburgs disease. Neurology 1988; 38: 1153.
12. Bauer HJ, Firnhaber W, Winkler W. Prognostic criteria in multiple sclerosis. Ann NY Acad Sci 1965; 122: 542.
13. Charcot JM. Histologie de la sclérose en plaques. Gazette Hôpital Paris 1868; 41: 554.
14. Charcot JM. Lectures on diseases of the nervous system. p. 157. Sigerson G [trans]. First series lectures 6,7,8 delivered 1868. London: The New Sydenham Society; 1877.
15. Kidd D, Revesz T. A comparative clinicopathological study of progressive multiple sclerosis [Abstract]. Ann Neurol 1993; 34: 308.
16. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
17. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Neurology 1993; 43: 910-8.
18. Rice GPA, Ebers GC. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol 1998; 55: 1578-80.
19. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E, et al. Primarily chronic progressive and relapsing remitting MS: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A 1989; 86: 7113-7.
20. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991 ; 29: 53-62.
21. 2 weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross sectional study. Eur Neurol 1998; 40: 91-8.
22. Kremenchutzky M, Lee D, Rice GPA, Ebers CG. Diagnostic brain MRI findings in Primary progressive multiple sclerosis. Multiple Sclerosis 2000; 6: 81-5.
23. Kremenchutzky M, Lee D, Rice GPA, Ebers GC. Multiple Sclerosis 2000; 6: 81-5.
24. Shyu WC, Lin JC, Chang BC, Harn HJ, Lee CC, Tsao WL. Recurrent ascending myelitis: an unusual presentation of herpes simplex virus type I infection. Ann Neurol 1993; 34: 625-7.
25. McAlpine D, Compston ND, Lumsden CE. Multiple sclerosis. Edinburgh: Livingstone; 1955.
26. McAlpine D, Lumsden CE, Acheson ED. Multiple sclerosis: a reappraisal. 2 ed. London: Churchill Livingstone; 1972. p. 214.
27. Weinshenker BG, Bass G, Rice GPA, Noseworthy J, Carriere W, Ebers GC, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
28. Cottrell D, Kremenchutzky M, Rice GPA, Hader W, Baskerville J, Ebers GC, et al. The natural history of multiple sclerosis: a geographically based study. V. Primary progressive multiple sclerosis. Brain 1999; 122: 625-39.
29. Ebers GC, Paty DW. Natural history studies and applications to clinical trials. In Paty DW, Ebers GC. Multiple sclerosis. Philadelphia: FA Davis; 1998. p. 193-228.
30. Bramwell B. The prognosis of disseminated sclerosis, duration in two hundred cases. Edin Med J 1917; 18: 16-23.
31. Brain WR. Prognosis of disseminated sclerosis. Lancet 1936; 2: 866-7
32. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol 1970; 22: 215-25
33. Compston A. Methods of genetic epidemiology in multiple sclerosis. In McAlpine's Multiple sclerosis. 3 ed. Churchill Livingstone Publishers; 1998. p. 46.
34. Wynn DR, Rodriguez M, O'Fallon, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780-6.
35. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in North East Scotland. J Neurol Neurosurg Psychiatry 1987; 50: 523-31.
36. Poser S, Kurtzke JF, Schlaf G. Survival in multiple sclerosis. J Clin Epidemiol 1989; 42: 159-68.
37. Riise T, Gronning M, Aarli JA, Nyland H, Larsen JP, Edland A. Prognostic factors for life expectancy in multiple sclerosis analyzed by Cox-models. J Clin Epidemiol 1988; 41: 1031-6.
38. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992; 42: 991-4.
39. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-6.
40. Kremenchutzky M, Sim D, Baskerville J, Rice GPA, Ebers GC. A study of the causes of death among multiple sclerosis patients. Neurology 2000; 50 (Suppl 3): A350.
41. Weinshenker B. The natural history of multiple sclerosis. Can J Neurol Sci 1987; 14: 255-61.
42. The INFB Multiple Sclerosis Study Group. Interferon beta 1-b in the treatment of multiple sclerosis. Neurology 1995; 45: 1277-85.
43. British and Dutch MS Azathioprine Trial Group. Double masked trial of azathioprine in multiple sclerosis. Lancet 1988; 2: 179-83.
44. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
45. Johnson KP, for the Copolymer 1 Study Group. Copolymer I reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
46. Ebers GC, Paty DW. Multiple sclerosis. Philadelphia: FA Davis; 1998.
47. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Ebers GC. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989; 112: 1419-28.
48. Kurtzke JF, et al. Studies on the natural history of multiple sclerosis. VII. Acta Neurol Scand 1973; 49: 379-95.
49. Kremenchutzky M, Baskerville J, Rice GPA, Ebers GC. Progressive relapsing and relapsing progressive multiple sclerosis: a re-evaluation [Abstract]. Multiple sclerosis 1998; 4: 102.
50. Kremenchutzky M, Cottrell DA, Rice GPA, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographicaly based study. VII. Progressive relapsing and relapsing progressive multiple sclerosis: a re-evaluation. Brain 1999; 122: 1941-50.
51. Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology 1988; 38: 617-21.
52. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 year follow up. Brain 1993; 116: 117-34.
53. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo controlled, randomized, double masked, variate dosage, clinical trial of azathioprine with and without methyl-prednisolone in multiple sclerosis. Neurology 1989; 39: 1018-26.
54. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo controlled, double blind, randomized, two center pilot trial of COP 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-9.
55. The MS Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis. Ann Neurol 1990; 27: 591-605.
56. The Canadian Cooperative MS Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6.
57. ESGISPMS (European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis). Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
58. PRISMS (Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
59. Cottrell DA, Kremenchutzky M, Rice GPA, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. V. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-39
60. Cottrell DA, Kremenchutzky M, Rice GPA, Hader W, Baskerville J, Ebers GC, et al. The natural history of multiple sclerosis: a geographically based study. VI. Applications to planing and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999; 122: 641-7.
61. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Ebers GC. The natural history of MS: a geographically based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-56.
62. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Baskerville J, Ebers GC. The natural history of MS: a geographically based study. IV. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057-67.
63. Sibley WA, Bamford CR, Clark K. Clinical viral infections and MS. Lancet 1985; 1: 1313-5.
64. Birk K, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990; 47: 738-42.
65. Clark VA, Detels R, Visscher BR, Valdiviezo NL, Malmgren RM, Dudley JP. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982; 248: 856-60.
66. Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP. Factors associated with a rapid course of multiple sclerosis. Arch Neurol 1982; 39: 337-41.
67. Jansson L, Holmdahl R. Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res 1998; 47: 290-301.